Form 8-K - Current report:
SEC Accession No. 0001437749-23-009194
Filing Date
2023-04-04
Accepted
2023-04-04 11:38:46
Documents
13
Period of Report
2023-04-04
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K atos20230403_8k.htm   iXBRL 8-K 21560
  Complete submission text file 0001437749-23-009194.txt   153029

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA atos-20230404.xsd EX-101.SCH 3600
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE atos-20230404_def.xml EX-101.DEF 11531
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE atos-20230404_lab.xml EX-101.LAB 15413
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atos-20230404_pre.xml EX-101.PRE 11687
7 EXTRACTED XBRL INSTANCE DOCUMENT atos20230403_8k_htm.xml XML 2568
Mailing Address 107 SPRING STREET SEATTLE WA 98104
Business Address 107 SPRING STREET SEATTLE WA 98104 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

EIN.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35610 | Film No.: 23795865
SIC: 2834 Pharmaceutical Preparations